title: Defining the level of evidence for technology adoption in the localized prostate cancer pathway.
abstract: New technologies in prostate cancer are attempting to change the current prostate cancer pathway by aiming to reduce harms while maintaining the benefits associated with screening, diagnosis, and treatment. In this article, we discuss the optimal evaluation that new technologies should undergo to provide level 1 evidence typically required to change the practice. With this in mind, we focus on feasible and pragmatic trials that could be delivered in a timely fashion by many centers while retaining primary outcomes that focus on clinically meaningful outcomes.
authors: Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK; Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Electronic address: massimo.valerio.12@ucl.ac.uk.
authors: Massimo
authors: M
authors: Valerio
authors: Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
authors: Ahmed
authors: A
authors: El-Shater Bosaily
authors: Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
authors: Mark
authors: M
authors: Emberton
authors: Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
authors: Hashim U
authors: HU
authors: Ahmed
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D006801:Humans; D061705:Image-Guided Biopsy / Q000379:methods*; D008297:Male; D011467:Prostate / Q000473:pathology*; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D011878:Radiotherapy / Q000379:methods; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
chemical_list: D000726:Androgen Antagonists
keywords: Focal therapy; Health technology assessment; MRI; Prostate cancer; Targeted biopsy; Trials